Computational models describing bacterial kinetics were developed for inhalational anthrax in New Zealand white (NZW) rabbits following inhalation of Ames strain B. anthracis. The data used to parameterize the models included bacterial numbers in the airways, lung tissue, draining lymph nodes, and blood. Initial bacterial numbers were deposited spore dose. The first model was a single exponential ordinary differential equation (ODE) with 3 rate parameters that described mucociliated (physical) clearance, immune clearance (bacterial killing), and bacterial growth. At 36 hours postexposure, the ODE model predicted 1.7×107 bacteria in the rabbit, which agreed well with data from actual experiments (4.0×107 bacteria at 36 hours). Next, building on the single ODE model, a physiological-based biokinetic (PBBK) compartmentalized model was developed in which 1 physiological compartment was the lumen of the airways and the other was the rabbit body (lung tissue, lymph nodes, blood). The 2 compartments were connected with a parameter describing transport of bacteria from the airways into the body. The PBBK model predicted 4.9×107 bacteria in the body at 36 hours, and by 45 hours the model showed all clearance mechanisms were saturated, suggesting the rabbit would quickly succumb to the infection. As with the ODE model, the PBBK model results agreed well with laboratory observations. These data are discussed along with the need for and potential application of the models in risk assessment, drug development, and as a general aid to the experimentalist studying inhalational anthrax.
Computational models describing bacterial kinetics were developed for inhalational anthrax in New Zealand white (NZW) rabbits following inhalation of Ames strain B. anthracis. The data used to parameterize the models included bacterial numbers in the airways, lung tissue, draining lymph nodes, and blood. These data are discussed along with the need for and potential application of the models in risk assessment, drug development, and as a general aid to the experimentalist studying inhalational anthrax.
Get full access to this article
View all access options for this article.
References
1.
TournierJN, Rossi PaccaniS, Quesnel-HellmannA, BaldariCT. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol Aspects Med, 2009; 30(6):456-466.
2.
FrankelAE, KuoSR, DostalD, et al. Pathophysiology of anthrax. Front Biosci, 2009; 14:4516-4524.
3.
PohankaM, SkladalP. Bacillus anthracis, Francisella tularensis and Yersinia pestis. The most important bacterial warfare agents-review. Folia Microbiol (Praha), 2009; 54(4):263-272.
4.
PassalacquaKD, BergmanNH. Bacillus anthracis: interactions with the host and establishment of inhalational anthrax. Future Microbiol, 2006; 1(4):397-415.
5.
FranzDR. Preparedness for an anthrax attack. Mol Aspects Med, 2009; 30(6):503-510.
6.
PileJC, MaloneJD, EitzenEM, FriedlanderAM. Anthrax as a potential biological warfare agent. Arch Intern Med, 1998; 158:429-434.
7.
BushLM, PerezMT. The anthrax attacks 10 years later. Ann Intern Med, 2011; 156(1 Pt 1):41-44.
8.
MatsumotoG. Anthrax powder: state of the art?. Science, 2003; 302:1492-1497.
9.
MacIntyreCR, SeccullA, LaneJM, PlantA. Development of a risk-priority score for category A bioterrorism agents as an aid for public health policy. Mil Med, 2006; 171:589-594.
10.
RaberE. The challenge of determining the need for remediation following a wide-area biological release. Biosecur Bioterror, 2011; 9(3):257-261.
11.
PricePN, SohnMD, LaCommareKSH, McWilliamsJA. Framework for evaluating anthrax risk in buildings. Environ Sci Technol, 2009; 43(6):1783-1787.
CanterDA. Addressing residual risk issues at anthrax cleanups: how clean is clean?. J Toxicol Environ Health Part A, 2005; 68:1017-1032.
14.
GutmannA. Safeguarding children—pediatric research on medical countermeasures. N Engl J Med, 2013; 368:1171-1173.
15.
BouzianasDG. Medical countermeasures to protect humans from anthrax bioterrorism. Trends Microbiol, 2009; 17(11):522-528.
16.
BaillieLW. Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol, 2006; 101(3):594-606.
17.
GoossensPL. Animal models of human anthrax: the quest for the Holy Grail. Mol Aspects Med, 2009; 30(6):467-480.
18.
CohenML, WhalenT. Implications of low level human exposure to respirable B. anthracis. Applied Biosafety, 2007; 12(2):109-115.
19.
WatsonA, KeirD. Information on which to base assessments of risk from environments contaminated with anthrax spores. Epidemiol Infect, 1994; 113:479-490.
20.
GuttingBW, NicholsTL, ChannelSR, et al. Inhalational anthrax (Ames aerosol) in naïve and vaccinated New Zealand rabbits: characterizing the spread of bacteria from lung deposition to bacteremia. Front Cell Infect Microbiol, 2012June28; 2:87.
21.
TwenhafelNA. Pathology of inhalation anthrax animal models. Vet Pathol, 2010; 47(5):819-830.
22.
YeeSB, HatkinJM, DyerDN, OrrSA, PittML. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment. Comp Med, 2010; 60:461-468.
23.
ZauchaGM, PittMLM, EstepJ, IvinsBE, FriedlanderAM. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med, 1998; 122:982-992.
24.
BuchnerH. Untersuchungen über den Durchtritt von Infection serregern durch die Intacte Lungenoberflache. J Hyg (Berlin), 1888; 8:145-245.
25.
DruettHA, HendersonDW, PackmanL, PeacockS. Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J Hyg (Lond), 1953; 51(3):359-371.
26.
HarperGJ, MortonJD. The respiratory retention of bacterial aerosols: experiments with radioactive spores. J Hyg (Lond), 1953; 51:372-385.
27.
JarabekAM, AsgharianB, MillerFJ. Dosimetric adjustments for interspecies extrapolation of inhaled poorly soluble particles (PSP). Inhal Toxicol, 2005; 17:317-344.
28.
RaabeOG, Al-BayatiMA, TeagueSB, RasoltA. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann Occ Hyg, 1988; 32:53-63.
29.
CoteCK, WelkosSL, BozueJ. Key aspects of the molecular and cellular basis of inhalational anthrax. Microbes Infect, 2011;(14-15):1146-1155.
Guidi-RontaniC. The alveolar macrophage: the Trojan horse of Bacillus anthracis. Trends Microbiol, 2002; 10(9):405-409.
32.
LincolnRE, KleinF, HodgesDR, HainesBW, RhianMA. Pathogenesis of anthrax—a progress report. Technical Memorandum 19. United States Army Biological Laboratories, Ft. Detrick. Project 4B92-02-034; 1962:1-87.
33.
RossJM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Path Bact, 1957; 73:485-494.
34.
FritzDL, JaaxNK, LawrenceWB, et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest, 1995; 73(5):691-702.
35.
LincolnRE, HodgesDR, KleinF, et al. Role of the lymphatics in the pathogenesis of anthrax. J Infect Dis, 1965; 115(5):481-494.
36.
BerdjisCC, GleiserCA, HartmanHA, KuehneRW, GochenourWS. Pathogenesis of respiratory anthrax in Macaca mulatta. B J Exp Pathol, 1962; 43(5):515-524.
37.
BrachmanPS. Inhalation anthrax. Ann NY Acad Sci, 1980; 353:83-93.
38.
AbramovaFA, GrinbergLM, YampolskayaOV, WalkerDH. Pathology of inhalation anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Nat Acad Sci U S A, 1993; 90:2291-2294.
39.
AlbrinkWS, BrooksSM, BironRE, KopelM. Human inhalational anthrax, a report of three fatal cases. Am J Pathol, 1960; 36:457-468.
40.
WeinerZP, GlomskiIJ. Updating perspectives on the initiation of Bacillus anthracis growth and dissemination through its host. Infect Immun, 2012; 80(5):1626-1633.
41.
TournierJN, CleretA, Quesnel-HellmannA. Letter to the editor: what is the relevance of lung epithelial cells during the dissemination of spores in inhalational anthrax?. Inf Immun, 2009; 77(1):565-566.
42.
GuttingBW, MarchetteD, SherwoodR, et al. Modeling low-dose mortality and disease incubation period of inhalational anthrax in the rabbit. J Theor Biol, 2013; 329:20-31.
43.
TaftS, HinesS. Benchmark dose analysis for Bacillus anthracis inhalation exposures in the nonhuman primate. Risk Anal, 2012; 32(10):1750-1768.
BartrandTA, WeirMH, HaasCN. Dose-response models for inhalation of Bacillus anthracis spores: interspecies comparisons. Risk Anal, 2008; 28:1115-1124.
46.
HaasC. On the risk of mortality to primates exposed to anthrax spores. Risk Anal, 2002; 22:189-193.
47.
WeirMH, HaasCN. A model for in-vivo delivered dose estimation for inhaled Bacillus anthracis spores in humans with interspecies extrapolation. Environ Sci Technol, 2011; 45:5828-5833.
48.
MayerBT, KoopmanJS, IonidesEL, PujolJM, EisenbergJNS. A dynamic dose-response model to account for exposure patterns in risk assessment: a case study in inhalation anthrax. J R Soc Interface, 2010; 8(57):506-517.
49.
PujolJM, EisenberbJE, HaasCN, KoopmanJS. The effect of ongoing exposure dynamics in dose response relationships. PLoS Comput Biol, 2009; 5(6):e1000399.
50.
WilkeningD. Modeling the incubation period of inhalational anthrax. Med Dec Making, 2008; 28:593-605.
51.
WilkeningD. Sverdlovsk revisited: modeling human inhalation anthrax. Proc Natl Acad Sci U S A, 2006; 103:7589-7594.
52.
BrookmeyerR, JohnsonE, BarryS. Modelling the incubation period of anthrax. Stat Med, 2005; 28:531-542.
53.
BrookmeyerR, BladesN, Hugh-JonesM, HendersonD. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics, 2001; 2:233-247.
54.
EganJR, LegrandJ, HallIM, CauchemezS, FergusonNM, LeachS. Re-assessment of mitigation strategies for deliberate release of anthrax using a real-time outbreak characterization tool. Epidemics, 2010; 2:189-194.
55.
BrookmeyerR, JohnsonE, BollingerR. Public health vaccination policies for containing an anthrax outbreak. Nature, 2004; 432:901-904.
56.
BrookmeyerR, JohnsonE, BollingerR. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak. Proc Natl Acad Sci U S A, 2003; 100(17):10129-10132.
57.
BrookmeyerR, BladesN. Prevention of inhalational anthrax in the U.S. outbreak. Science, 2002; 295:1861.
58.
DayJ, FriedmanA, SchlesingerLS. Modeling the host response to inhalation anthrax. J Theor Biol, 2011; 276:199-208.
59.
KumarR, ChowCC, BartelsJD, ClermontG, VodovotzY. A mathematical simulation of the inflammatory response to anthrax infection. Shock, 2008; 29(1):104-111.
FellowsPF, LinscottMK, IvinsBE, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine, 2001; 19:3241-3247.
62.
PittML, LittleSF, IvinsBE, et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine, 2001; 19:4768-4773.
63.
JaySJ, JohansonWGJr, PierceAK, ReischJS. Determinants of lung bacterial clearance in normal mice. J Clin Invest, 1976; 57:811-817.
64.
Environmental Protection Agency. Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment; 2006; EPA/600/R-05/043F.
65.
WelkosS, FriedlanderA, WeeksS, LittleS, MendelsonI. In-vitro characterization of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J Med Microbiol, 2002; 51:821-831.
66.
Guidi-RontaniC, Weber-LevyM, LabruyereE, MockM. Germination of Bacillus anthracis spores within alveolar macrophages. Mol Microbiol, 1999; 31(1):9-17.
67.
ShafaF, MoberlyBJ, GerardtP. Cytological features of anthrax spores phagocytized in vitro by rabbit alveolar macrophages. J Infect Dis, 1966; 116(4):401-411.
68.
CoteCK, BozueJ, MoodyKL, DiMezzoTL, ChapmanCE, WelkosSL. Analysis of a novel spores antigen in Bacillus anthracis that contributes to spore opsonization. Microbiology, 2008; 154:619-635.
69.
CoteCK, RossiCA, KangAS, MorrowPR, LeeJS, WelkosSL. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microbial Path, 2005; 38:209-225.
70.
WelkosS, LittleS, FriedlanderA, FritzD, FellowsP. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology, 2001; 147:1677-1685.
71.
BarnesJM. The development of anthrax following the administration of spores by inhalation. Br J Exp Pathol, 1947; 28(6):385-394.
72.
LipscombJC, HaddadS, PoetT, KrishnanK. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. Adv Exp Med Biol, 2012; 745:76-95.
73.
TanYM, ClewellH, CampbellJ, AndersonM. Evaluating pharmacokinetic and pharmacodynamic interactions with computational models in supporting cumulative risk assessment. Int J Environ Res Public Health, 2011; 8(5):1613-1630.
HughesR, MayAJ, WiddicombeJG. The output of lymphocytes from the lymphatic system of the rabbit. J Physiol, 1956; 132:834-390.
76.
WiddicombeJG, HughesR, MayAJ. The role of the lymphatic system in the pathogenesis of anthrax. Br J Exp Pathol, 1956; 37(4):343-349.
77.
BensmanMD, MackieRS, MinterZA, GuttingBW. The effect of animal sera on Bacillus anthracis Sterne spore germination and vegetative cell growth. J Appl Microbiol, 2012; 113(2):276-283.
78.
ShafaF, MoberlyBJ, GerardtP. Cytological features of anthrax spores phagocytized in vitro by rabbit alveolar macrophages. J Infect Dis, 1966; 116(4):401-411.
